Pfizer Stock News

A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years.

This article highlights the October 2025 ReFa/Ro Dogs, focusing on high-yield, low-priced dividend stocks for contrarian income investors. Top projected net gainers include MFA, CIM, HAFN, IPG, and LYB, with analysts forecasting 30.84% to 70.61% upside by October 2026. Nine of the top ten ReFa/Ro Dogs meet the 'ideal' criterion: dividends from $1,000 invested exceed their share price, emphasizi...

Following Pfizer's victory over Novo Nordisk in the "war" for Metsera, its stock resumed its upward momentum. But before the deal was completed, it again beat Wall Street analysts' consensus EPS and revenue estimates by a wide margin. Lorbrena, an ALK inhibitor against non-small cell lung cancer, brought in $268 million for Pfizer in Q3, up 30.1% year-on-year.

Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve claims over alleged quality control lapses in medicine to treat attention deficit hyperactivity disorder in children, Texas Attorney General Ken Paxton said on Wednesday.

Pfizer Inc. ( PFE ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants David Denton - Executive VP & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good morning, everyone. I hope you're all doing well.

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.

Pfizer's acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach $130 billion by 2030. Viking Therapeutics has both injectable and oral versions of its dual-action, weight-loss drug in advanced testing, making it an attractive acquisition target.

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon.